Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
9.73
+0.05 (0.52%)
Apr 20, 2026, 11:37 AM EDT - Market open
Kura Oncology Revenue
In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth. Kura Oncology had revenue of $17.34M in the quarter ending December 31, 2025, a decrease of -67.83%.
Revenue (ttm)
$67.48M
Revenue Growth
+25.24%
P/S Ratio
12.73
Revenue / Employee
$259,546
Employees
260
Market Cap
863.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.48M | 13.60M | 25.24% |
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Maravai LifeSciences Holdings | 185.74M |
| Theravance Biopharma | 107.46M |
| Lexicon Pharmaceuticals | 49.80M |
| Allogene Therapeutics | 22.00K |
KURA News
- 3 days ago - Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results - Benzinga
- 3 days ago - Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib - GlobeNewsWire
- 11 days ago - Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 - GlobeNewsWire
- 17 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Kura Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire